Immunocore (IMCR) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $29.48, +4.02% vs the prior close of $28.34.
- Volume 378.20K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
IMCR jumps 4.0% to $29.48. Closed at $29.48, +4.02% vs the prior close of $28.34. Day range $28.73–$29.90, opened at $28.73.
IMCR daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — IMCR jumps 4.0% to $29.48
- Closed at $29.48, +4.02% vs the prior close of $28.34. Day range $28.73–$29.90, opened at $28.73.
- Volume was 378.20K shares, 0.9x its 50-day average of 410.97K.
- Price is -11.1% vs its 50-day average ($33.15) and -7.5% vs its 200-day average ($31.87).
- 52-week range $27.50–$40.72; today's close sits at 15% of that range, 27.6% below the 52-week high.
Oct 14, 2026 — IMCR rises 1.9% to $28.34
- Closed at $28.34, +1.87% vs the prior close of $27.82. Day range $27.50–$28.45, opened at $27.60.
- Volume was 414.30K shares, 1.0x its 50-day average of 414.21K.
- Price is -14.7% vs its 50-day average ($33.23) and -11.2% vs its 200-day average ($31.90).
- 52-week range $27.50–$40.72; today's close sits at 6% of that range, 30.4% below the 52-week high.
Oct 13, 2026 — IMCR slides 4.2% to $27.82, a 3-month low on 2.2x normal volume
- Closed at $27.82, -4.20% vs the prior close of $29.04. Day range $27.65–$29.25, opened at $29.00.
- Volume was 904.50K shares, 2.2x its 50-day average of 409.04K — unusually heavy trading.
- Price is -16.5% vs its 50-day average ($33.33) and -12.9% vs its 200-day average ($31.94).
- 52-week range $27.56–$40.72; today's close sits at 2% of that range, 31.7% below the 52-week high.
Oct 12, 2026 — IMCR dips 1.2% to $29.04, a 3-month low
- Closed at $29.04, -1.19% vs the prior close of $29.39. Day range $29.02–$29.73, opened at $29.48.
- Volume was 219.70K shares, 0.5x its 50-day average of 419.88K — lighter than usual.
- Price is -13.1% vs its 50-day average ($33.42) and -9.2% vs its 200-day average ($31.98).
- 52-week range $27.56–$40.72; today's close sits at 11% of that range, 28.7% below the 52-week high.
Oct 9, 2026 — IMCR rises 1.0% to $29.39
- Closed at $29.39, +1.03% vs the prior close of $29.09. Day range $29.03–$29.73, opened at $29.06.
- Volume was 452.80K shares, 1.1x its 50-day average of 415.08K.
- Price is -12.3% vs its 50-day average ($33.52) and -8.2% vs its 200-day average ($32.02).
- 52-week range $27.56–$40.72; today's close sits at 14% of that range, 27.8% below the 52-week high.
Oct 8, 2026 — IMCR dips 1.1% to $29.09, a 3-month low, 5 down days in a row
- Closed at $29.09, -1.09% vs the prior close of $29.41. Day range $28.66–$29.62, opened at $29.19.
- Volume was 424.50K shares, 1.0x its 50-day average of 410.44K.
- Price is -13.4% vs its 50-day average ($33.60) and -9.2% vs its 200-day average ($32.05).
- 52-week range $27.56–$40.72; today's close sits at 12% of that range, 28.6% below the 52-week high.
- That makes 5 straight losses.
Oct 7, 2026 — IMCR dips 0.5% to $29.41, a 3-month low, 4 down days in a row
- Closed at $29.41, -0.47% vs the prior close of $29.55. Day range $29.15–$29.82, opened at $29.55.
- Volume was 343.80K shares, 0.8x its 50-day average of 407.71K.
- Price is -12.7% vs its 50-day average ($33.69) and -8.3% vs its 200-day average ($32.09).
- 52-week range $27.56–$40.72; today's close sits at 14% of that range, 27.8% below the 52-week high.
- That makes 4 straight losses.
Oct 6, 2026 — IMCR ends flat (-0.1%) to $29.55, a 3-month low, 3 down days in a row
- Closed at $29.55, -0.14% vs the prior close of $29.59. Day range $29.40–$30.34, opened at $29.93.
- Volume was 662.60K shares, 1.7x its 50-day average of 401.04K.
- Price is -12.5% vs its 50-day average ($33.77) and -8.0% vs its 200-day average ($32.12).
- 52-week range $27.56–$40.72; today's close sits at 15% of that range, 27.4% below the 52-week high.
- That makes 3 straight losses.
Oct 5, 2026 — IMCR dips 0.4% to $29.59, a 3-month low
- Closed at $29.59, -0.40% vs the prior close of $29.71. Day range $29.39–$30.48, opened at $29.98.
- Volume was 329.40K shares, 0.8x its 50-day average of 405.06K.
- Price is -12.6% vs its 50-day average ($33.86) and -8.0% vs its 200-day average ($32.15).
- 52-week range $27.56–$40.72; today's close sits at 15% of that range, 27.3% below the 52-week high.
Oct 2, 2026 — IMCR dips 2.7% to $29.71, a 3-month low
- Closed at $29.71, -2.72% vs the prior close of $30.54. Day range $29.23–$30.79, opened at $30.78.
- Volume was 657.60K shares, 1.6x its 50-day average of 402.91K.
- Price is -12.5% vs its 50-day average ($33.97) and -7.7% vs its 200-day average ($32.18).
- 52-week range $27.56–$40.72; today's close sits at 16% of that range, 27.0% below the 52-week high.
IMCR latest news & SEC filings
Every SEC filing by or about IMCR in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $115.93M (prior year $97.96M) (+18.3% vs Jun 30, 2025)
- Net income: -$808.00K (prior year -$10.30M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.02 (prior year -$0.20) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade IMCR
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Feb 25, 2026, Jan 9, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.41% (largest 4.2%).
- Liquidity: about 456.92K shares (≈$13.47M) trade per day on average.
- 52-week position: $29.48 vs a range of $27.50–$40.72 (15% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 11 sales; latest: Leger Tina Amber St sold 1,000 shares on Feb 18, 2026.
- Latest filings: 8-K Sep 14, 2026; 10-Q Aug 6, 2026; 8-K Aug 6, 2026.
- Share count: 51.50M shares outstanding (Jul 31, 2026), +2.2% vs a year earlier.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
IMCR market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 28.73 | 29.90 | 28.73 | 29.48 | 378.20K |
| Oct 14, 2026 | 27.60 | 28.45 | 27.50 | 28.34 | 414.30K |
| Oct 13, 2026 | 29.00 | 29.25 | 27.65 | 27.82 | 904.50K |
| Oct 12, 2026 | 29.48 | 29.73 | 29.02 | 29.04 | 219.70K |
| Oct 9, 2026 | 29.06 | 29.73 | 29.03 | 29.39 | 452.80K |
| Oct 8, 2026 | 29.19 | 29.62 | 28.66 | 29.09 | 424.50K |
| Oct 7, 2026 | 29.55 | 29.82 | 29.15 | 29.41 | 343.80K |
| Oct 6, 2026 | 29.93 | 30.34 | 29.40 | 29.55 | 662.60K |
| Oct 5, 2026 | 29.98 | 30.48 | 29.39 | 29.59 | 329.40K |
| Oct 2, 2026 | 30.78 | 30.79 | 29.23 | 29.71 | 657.60K |
| Oct 1, 2026 | 30.38 | 31.19 | 30.06 | 30.54 | 769.70K |
| Sep 30, 2026 | 30.90 | 31.28 | 30.22 | 30.29 | 622.90K |
| Sep 29, 2026 | 30.78 | 30.93 | 30.27 | 30.85 | 344.20K |
| Sep 28, 2026 | 30.70 | 30.92 | 30.10 | 30.64 | 266.60K |
| Sep 25, 2026 | 31.35 | 31.35 | 30.43 | 30.72 | 272.00K |
| Sep 24, 2026 | 31.55 | 33.86 | 30.71 | 31.29 | 640.60K |
| Sep 23, 2026 | 32.42 | 32.42 | 31.10 | 31.54 | 411.70K |
| Sep 22, 2026 | 32.83 | 32.83 | 31.82 | 32.42 | 281.30K |
| Sep 21, 2026 | 32.00 | 32.45 | 31.88 | 32.18 | 266.00K |
| Sep 18, 2026 | 32.07 | 32.65 | 31.63 | 32.00 | 475.90K |
About Immunocore
Immunocore (IMCR) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in OXFORDSHIRE, United Kingdom. State of incorporation: United Kingdom. Fiscal year ends December 31. SEC CIK 1671927.
IMCR board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| John Irving Bell | Director | May 28, 2026 |
| Roy Steven Herbst | Director | May 28, 2026 |
| Bahija Jallal | CHIEF EXECUTIVE OFFICER | Feb 19, 2026 |
| Siddharth Kaul | Director | May 28, 2026 |
| William Pao | Director | May 28, 2026 |
| Kristine Peterson | Director | May 28, 2026 |
| Peter John Ratcliffe | Director | May 28, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| David M Berman | HEAD OF R&D | Feb 19, 2026 |
| Travis Alan Coy | Chief Financial Officer | Feb 19, 2026 |
| John Goll | SVP, FINANCE & CAO | Feb 19, 2026 |
| Bahija Jallal | CHIEF EXECUTIVE OFFICER | Feb 19, 2026 |
| Leger Tina Amber St | CHIEF HR OFFICER | Feb 19, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Feb 18, 2026 | Leger Tina Amber St | Sale | 1,000 | $32.35 |
| Feb 18, 2026 | Bahija Jallal | Sale | 11,474 | $32.35 |
| Feb 18, 2026 | David M Berman | Sale | 5,965 | $32.35 |
| Feb 18, 2026 | John Goll | Sale | 698 | $32.35 |
| Dec 5, 2025 | David M Berman | Sale | 572 | $40.14 |
| Dec 4, 2025 | David M Berman | Sale | 31,341 | $40.26 |
| Nov 28, 2025 | David M Berman | Sale | 5,521 | $40.09 |
| Nov 26, 2025 | David M Berman | Sale | 69,404 | $40.12 |
| Nov 25, 2025 | David M Berman | Sale | 18,020 | $40.03 |
| Nov 24, 2025 | David M Berman | Sale | 100 | $40.00 |
| Sep 30, 2025 | David M Berman | Sale | 61,849 | $35.23 |
IMCR financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $400.02M | $-35.51M | -0.71 | $-10.71M |
| Dec 31, 2024 | $310.20M | $-51.09M | -1.02 | $26.06M |
| Dec 31, 2023 | $249.43M | $-55.29M | -1.13 | $2.94M |
| Dec 31, 2022 | $174.36M | $-52.54M | -1.15 | $-49.21M |
| Dec 31, 2021 | $4.08M | $-180.03M | -4.24 | $-143.11M |
Latest balance sheet: total assets $1.12B, total liabilities $699.62M, cash $484.92M (as of Jun 30, 2026).
IMCR earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $34.50 |
| May 6, 2026 | 8-K Item 2.02 (results) | $30.73 |
| Feb 25, 2026 | 8-K Item 2.02 (results) | $32.16 |
| Jan 9, 2026 | 8-K Item 2.02 (results) | $33.00 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $31.59 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $31.93 |
| May 7, 2025 | 8-K Item 2.02 (results) | $29.92 |
| Feb 26, 2025 | 8-K Item 2.02 (results) | $30.77 |
| Jan 10, 2025 | 8-K Item 2.02 (results) | $30.40 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $33.51 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on IMCR
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.